By Modupe Gbadeyanka
Managing Director/Chief Executive Officer of Neimeth Pharmaceuticals, Mr Matthew Azoji, has hinted that the company will soon launch a five-year strategic growth plan expected to propel the firm into greatness.
Mr Azoji, in a statement issued in Lagos, was quoted as saying that this policy would benefit shareholders of Neimeth because it would bring about good value to their investment in the company and also provide services that will delight all stakeholders.
“Our strategic plan is to move Neimeth from a good company to a great company. We shall soon launch a five-year strategic plan to reposition the company to play greater roles in the healthcare industry, ensure good returns on investment for shareholders and provide services that will delight all stakeholders,” the Managing Director said.
His revelation followed Neimeth’s performance at the just-concluded 2019 PEARL Awards, where the organisation won the Sectoral Leadership Award for the healthcare (pharmaceuticals) sector of the Nigerian Stock Exchange (NSE).
The feat was in recognition of the company’s performance in the Nigerian capital market and Neimeth grabbed the award ahead of two other firms listed on the stock exchange and nominated for the category.
Receiving the award at the event, Mr Azoji said, “The PEARL award and others before it are certificates that will motivate us to strive to do better.”
According to him, Neimeth, since its establishment, had since metamorphosed into a known brand in the Nigerian healthcare industry to make products that met international standards.
The over 61-year old company, which used to be an arm of a foreign transnational, Pfizer Incorporated, became Neimeth International Pharmaceuticals Plc in May 1997 through a management buyout of the United States investors to become a wholly owned indigenous firm.
